Texas AG sues makers of Tylenol, claiming they hid alleged links to autism

Texas Attorney General Ken Paxton has sued Johnson & Johnson and its consumer health spinoff Kenvue, alleging deceptive marketing of Tylenol to pregnant women despite purported links to autism and other neurodevelopmental disorders. Kenvue strongly refutes these claims, asserting acetaminophen is the safest pain relief option for pregnant women and citing the global medical community's consensus on its safety, alongside a recent NIH-funded study that found no increased risk. This state-level lawsuit, the first of its kind, introduces potential legal and reputational risks for the companies, although similar civil suits have previously been dismissed due to insufficient evidence, and major medical organizations continue to recommend acetaminophen for pregnant patients.

Analysis

Texas Attorney General Ken Paxton has initiated a lawsuit against Johnson & Johnson (JNJ) and its consumer health spinoff Kenvue (KVUE), alleging deceptive marketing of Tylenol to pregnant women despite purported links to autism and other neurodevelopmental disorders. This marks the first state-level lawsuit of its kind, following previous claims by former President Trump regarding Tylenol's safety during pregnancy. Kenvue, which spun off from J&J in 2023, strongly refutes these claims, asserting acetaminophen's safety and efficacy for pregnant women.

Kenvue's defense highlights that acetaminophen is widely considered the safest pain reliever for pregnant women, citing potential risks from untreated conditions like fever. The company also points to the global medical community's consensus on acetaminophen's safety and an April 2024 NIH-funded JAMA study that found no link between prenatal acetaminophen use and increased risk of autism or ADHD. This directly contradicts the lawsuit's premise and aligns with statements from organizations like the American College of Obstetricians and Gynecologists (ACOG).

The lawsuit faces significant challenges, as a similar civil suit against Kenvue was previously dismissed due to lack of evidence, with an appeal hearing set for November. Senator Bill Cassidy, a medical doctor, also criticized the lawsuit, citing weak evidence and medical science supporting acetaminophen's safety. The article notes Paxton's political motivations, including his Senate primary race against John Cornyn, suggesting the lawsuit may align with Trump's public statements on the issue.

Key Decisions for Investors

• Monitor the legal proceedings closely, as the outcome could set precedents for future litigation against JNJ and KVUE despite prior dismissals and strong medical counter-arguments.
• Evaluate the potential for reputational damage and increased regulatory scrutiny on pharmaceutical marketing, even if the lawsuit lacks scientific merit.
• Consider the political context surrounding the lawsuit, which may influence its trajectory and public perception, rather than solely focusing on scientific evidence.